At the 44th Annual J.P. Morgan Healthcare Conference, Bayer Aktiengesellschaft’s Pharmaceuticals Division outlined a clear financial roadmap: return to mid-single-digit percentage revenue growth by 2027 and achieve an operating margin of approximately 30% by 2030. In 2025 the division recorded five pivotal global drug approvals, underscoring its execution strength. Management highlighted that revenue from newly launched products grew by over 20% year-on-year, while R&D intensity remains above 16% of sales. Cost-reduction measures and organizational delayering are expected to deliver savings of €1.5 billion by 2026, supporting reinvestment in high-value pipeline assets and commercial expansion in key markets including the United States, EU and Japan.

Bayer emphasized landmark Phase III data for asundexian, a once-daily oral Factor XIa inhibitor for secondary stroke prevention: the OCEANIC-STROKE trial met both safety and efficacy endpoints, positioning the drug for blockbuster potential in a market where 20–30% of the 12 million annual stroke survivors face recurrence. Asundexian has received Fast Track designation from the U.S. FDA. Separately, finerenone (Kerendia®) secured FDA and Japanese MHLW approvals for heart failure patients with left ventricular ejection fraction ≥40%, building on its established chronic kidney disease indication. Ongoing Phase III programs MOONRAKER and THUNDERBALL are evaluating finerenone across broader cardio-renal indications, with topline results expected in mid-2026. The division also reported Phase II progress on AB-1002, a single-dose gene therapy for congestive heart failure, and initiation of Phase II and Phase I studies for a DVT-targeted antibody (BAY-3018250) and a GIRK4 inhibitor (BAY-3670549), respectively.

Bayer’s oncology business continues to scale globally, driven by Nubeqa® (darolutamide) which has treated over 200,000 prostate cancer patients worldwide and is on track for a third regulatory approval in China in 2026. Hyrnuo® (sevabertinib) received accelerated approval from the FDA for HER2-mutant non-small cell lung cancer and holds Breakthrough Therapy Designations in both the U.S. and China. The EORTC PEACE III study of radium-223 dichloride (Xofigo®) in combination with enzalutamide met its primary endpoint, and an additional Phase III radium-223 trial will conclude in 2026 to inform future filings. Bayer’s early-stage oncology pipeline includes KRAS-mutant inhibitors, next-generation targeted radionuclide therapies for hepatocellular carcinoma, and a PRMT5 inhibitor for MTAP-deleted tumors, all advancing through Phase I, reinforcing its commitment to precision oncology.